PRQR revenueFY2025€15.91M
- FY YoY
- -15.9%
- 5Y CAGR
- +119.4%
PRQR revenue was €15.91M for fiscal 2025 (ended Dec 31, 2025), down 15.9% from fiscal 2024. Compound annual growth was +119.4% over 5 years. It rose in 4 of the last 5 fiscal years.
ProQR Therapeutics N.V. (PRQR) financials
For fiscal 2025 (ended Dec 31, 2025), ProQR Therapeutics N.V. reported €15.91M of revenue and -€42.18M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €15.91M
- Revenue growth, YoY
- -15.9%
- Net income, FY2025
- -€42.18M
- Net margin
- -265.2%
- Free cash flow, FY2025
- -€53.81M
- EPS, diluted, FY2025
- -€0.40
- Cash
- €92.41M
- Total debt
- €4.87M
FY2020FY2025
FY2016FY2025
FY2016FY2025
PRQR revenue and earnings growth
PRQR net incomeFY2025-€42.18M
PRQR net income was -€42.18M for fiscal 2025 (ended Dec 31, 2025), compared with -€27.76M in fiscal 2024.
PRQR EPSFY2025-€0.40
PRQR diluted EPS was -€0.40 for fiscal 2025 (ended Dec 31, 2025), compared with -€0.32 in fiscal 2024.
PRQR free cash flowFY2025-€53.81M
PRQR free cash flow was -€53.81M for fiscal 2025 (ended Dec 31, 2025), compared with -€37.81M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €15.91M | €18.91M | €6.51M | €3.59M | €1.33M | €313.0K | - | - | - | - |
| Research and development | €44.73M | €36.36M | €25.15M | €50.87M | €42.22M | €38.13M | €46.49M | €29.51M | €31.15M | €31.92M |
| Selling, general and admin | €15.06M | €13.66M | €16.24M | €18.65M | €17.37M | €13.69M | €12.89M | €12.54M | €10.84M | €9.48M |
| Operating income | -€43.45M | -€30.47M | -€31.86M | -€65.16M | -€57.21M | -€42.37M | -€57.45M | -€36.29M | -€40.50M | -€39.57M |
| Interest expense | €929.0K | €1.08M | €1.20M | €5.13M | €3.40M | €2.04M | €1.08M | - | - | - |
| Pre-tax income | -€42.16M | -€27.96M | -€27.81M | -€64.11M | -€60.68M | -€46.49M | -€56.61M | -€37.09M | -€43.67M | -€39.10M |
| Income tax | €19.0K | -€197.0K | -€78.0K | €96.0K | €117.0K | €124.0K | €132.0K | €1.0K | €2.0K | - |
| Net income | -€42.18M | -€27.76M | -€28.12M | -€64.42M | -€60.74M | -€46.56M | -€56.48M | -€36.89M | -€43.64M | -€39.10M |
| EPS, basic | -€0.40 | -€0.32 | -€0.35 | -€0.90 | -€0.95 | -€0.93 | -€1.38 | - | - | - |
| EPS, diluted | -€0.40 | -€0.32 | -€0.35 | -€0.90 | -€0.95 | -€0.93 | -€1.38 | - | - | - |
| Diluted shares | 105.3M | 86.1M | 81.0M | 71.6M | 64.2M | 50.1M | 41.0M | 34.1M | 25.4M | 23.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | €92.41M | €149.41M | €118.92M | €94.78M | €187.52M | €75.84M | €111.95M | €105.58M | €48.10M | €59.20M |
| Receivables | €6.80M | €3.75M | - | - | - | - | - | - | - | - |
| Current assets | €100.13M | €153.84M | €120.99M | €154.46M | €191.48M | €80.02M | €114.67M | €108.37M | €50.56M | €62.02M |
| Total assets | €112.76M | €167.96M | €137.88M | €171.32M | €209.58M | €98.73M | €117.53M | €110.23M | €53.10M | €65.54M |
| Current liabilities | €32.44M | €38.90M | €34.20M | €20.99M | €27.60M | €10.30M | €10.99M | €8.16M | €8.49M | €6.71M |
| Short-term debt | €4.87M | €4.58M | - | €2.50M | €4.77M | - | - | - | - | - |
| Long-term debt | - | - | €4.29M | €4.27M | €39.32M | €16.19M | €12.71M | €9.39M | €5.28M | €5.70M |
| Total debt | €4.87M | €4.58M | €4.29M | €6.77M | €44.09M | €16.19M | €12.71M | €9.39M | €5.28M | €5.70M |
| Total liabilities | €63.38M | €79.40M | €96.49M | €104.64M | €96.35M | €42.18M | €23.70M | €17.55M | €13.78M | €12.41M |
| Shareholders' equity | €49.37M | €88.56M | €41.39M | €66.68M | €114.11M | €56.55M | €93.83M | €92.69M | €39.33M | €53.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -€52.79M | -€36.39M | €21.55M | -€68.51M | -€26.01M | -€47.06M | -€43.97M | -€28.49M | -€34.95M | -€34.22M |
| Capital expenditures | €1.02M | €1.42M | €1.37M | €708.0K | €484.0K | €924.0K | €580.0K | €312.0K | €121.0K | €2.54M |
| Free cash flow | -€53.81M | -€37.81M | €20.18M | -€69.22M | -€26.50M | -€47.98M | -€44.55M | -€28.80M | -€35.07M | -€36.76M |
| Investing cash flow | -€1.02M | -€4.07M | €4.28M | -€702.0K | -€425.0K | -€924.0K | -€580.0K | -€312.0K | -€121.0K | -€2.54M |
| Financing cash flow | -€1.84M | €70.28M | -€2.27M | -€30.89M | €136.83M | €14.50M | €50.20M | €86.46M | €26.64M | €357.0K |
| Stock-based compensation | €4.01M | €2.54M | €3.11M | €2.87M | €6.22M | €7.84M | €9.11M | €5.41M | €4.02M | €2.45M |
| Depreciation and amortization | - | - | - | - | €2.33M | €2.35M | €2.05M | €992.0K | €1.06M | €1.25M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -15.9% | 190.2% | 81.2% | 169.2% | 326.5% | - | - | - | - | - |
| Operating margin | -273.1% | -161.2% | -489.1% | -1813.0% | -4285.4% | -13536.1% | - | - | - | - |
| Net margin | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | -14877.0% | - | - | - | - |
| Free cash flow margin | -338.3% | -200.0% | 309.7% | -1925.9% | -1984.7% | -15330.4% | - | - | - | - |
| Return on equity | -85.4% | -31.3% | -67.9% | -96.6% | -53.2% | -82.3% | -60.2% | -39.8% | -111.0% | -73.6% |
| Return on assets | -37.4% | -16.5% | -20.4% | -37.6% | -29.0% | -47.2% | -48.1% | -33.5% | -82.2% | -59.7% |
| Current ratio | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.28 | 5.95 | 9.24 |
| Debt to equity | 0.10 | 0.05 | 0.10 | 0.10 | 0.39 | 0.29 | 0.14 | 0.10 | 0.13 | 0.11 |
Source: XBRL data ProQR Therapeutics N.V. files with the SEC, latest filing dated Mar 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
PRQR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PRQR | €15.91M | -15.9% | -€42.18M | -265.2% | $194.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PRQR FAQ
8 questionsWhat is PRQR revenue?
ProQR Therapeutics N.V. (PRQR) reported €15.91M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 15.9% from the year before.Is PRQR profitable?
No. ProQR Therapeutics N.V. reported a net loss of €42.18M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PRQR have?
ProQR Therapeutics N.V. reported €92.41M in cash and cash equivalents and €4.87M of debt on its most recent balance sheet in SEC filings.How fast is PRQR revenue growing?
ProQR Therapeutics N.V.'s revenue changed -15.9% in fiscal 2025, to €15.91M. Its compound annual growth rate was +119.4% over 5 years.What is PRQR free cash flow?
ProQR Therapeutics N.V. generated -€53.81M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€52.79M less capital expenditures.What is PRQR earnings per share?
Diluted earnings per share were -€0.40 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PRQR last report financial results?
The latest statements here come from ProQR Therapeutics N.V.'s 20-F filed on Mar 12, 2026, covering the period ended Dec 31, 2025.Where does this PRQR financial data come from?
Quantisnow builds these statements from the structured XBRL data ProQR Therapeutics N.V. files with the SEC. It is provided for information only and is not investment advice.